How to access Aimovig for migraine prevention from the UAE: 2026 pathway via UAE neurology and pharmacy supply
*Clinically reviewed by Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last reviewed 2026-05-20.
The UAE has one of the deepest neurology service networks in the wider region. Cleveland Clinic Abu Dhabi's neurology institute, Mediclinic City and Mediclinic Parkview, NMC Specialty and Aster Hospitals across Dubai and Sharjah, Burjeel Medical City, American Hospital Dubai, Saudi German Hospital Dubai, and the Dr Sulaiman Al Habib network in Dubai all run neurology services that treat migraine from acute attacks through conventional oral preventives and into the calcitonin gene-related peptide (CGRP) era. Aimovig (erenumab-aooe) was the first CGRP-receptor antagonist approved by the FDA, in May 2018, and was followed into the MENA market by its CGRP-ligand counterparts (Ajovy, Emgality, Vyepti) and by the oral gepants (Qulipta, Nurtec, Ubrelvy). For a UAE-resident adult with at least 4 migraine days per month, who has tried and failed two or more conventional oral preventives, the operational question is no longer whether CGRP-targeted preventive therapy is reachable: it is whether Aimovig or one of the anti-ligand mAbs is the right fit, how the prescription is dispensed, what insurance will and will not cover, and how the family handles the monthly self-injection routine over a multi-year treatment course.
This page explains how the pathway works in 2026 for a UAE-resident patient: who qualifies, where the prescribing neurologist conversation happens, how Aimovig is dispensed and stored, what the monthly dosing schedule looks like, what the realistic out-of-pocket exposure band is in AED, what to monitor (constipation and blood pressure being the notable signals), and how the longer-term treatment course fits into a UAE patient's life. It is concierge documentation written for a patient who is already in conversation with a treating neurologist and wants the operational reality laid out plainly.
Why Aimovig, and why now
Aimovig is erenumab-aooe, a humanised IgG2 monoclonal antibody that binds to and blocks the calcitonin gene-related peptide receptor. CGRP is a neuropeptide centrally involved in migraine pathophysiology. By antagonising the receptor itself, rather than the ligand, Aimovig blocks CGRP signalling at the receptor level. It is the only first-in-class CGRP-receptor mAb on the market. The competing anti-CGRP mAbs (Ajovy, Emgality, Vyepti) bind the CGRP ligand instead; the gepants (Qulipta, Nurtec, Ubrelvy) are small-molecule oral CGRP-receptor antagonists. The mechanism distinction matters mainly for switching decisions and for the side-effect profile.
The FDA approved Aimovig in May 2018, the first of the anti-CGRP preventive class. The EMA approved it in July 2018. The pivotal trials (STRIVE and ARISE in episodic migraine, plus the chronic-migraine programme and the LIBERTY refractory-population trial) demonstrated meaningful reduction in monthly migraine days versus placebo, with 50% response rates of 40 to 50 percent in episodic migraine across the 70 mg and 140 mg arms.
For a UAE patient who has cycled through topiramate, propranolol, amitriptyline, candesartan, flunarizine, or valproate at various points (often with inadequate effect, dose-limiting side effects, or both), Aimovig is the operational pathway to a once-monthly preventive that is mechanism-targeted at migraine biology rather than borrowed from epilepsy, cardiology, or psychiatry. The conversation about whether to start with Aimovig versus one of the anti-ligand mAbs versus an oral gepant like Qulipta is the central clinical decision. This page is the operational layer underneath that conversation.
What Aimovig is, in plain language
Aimovig is a subcutaneous injection. There is no infusion centre, no inpatient stay, no specialty-centre referral required. After an initial training session with the prescribing neurologist or a Novartis nurse educator, the patient self-injects at home. The device is the SureClick single-use prefilled autoinjector, or a single-use prefilled syringe for patients who prefer manual control.
The standard adult dose is 70 mg subcutaneous once monthly. The neurologist may increase to 140 mg once monthly for patients who need additional preventive benefit. The 140 mg dose is delivered as either one 140 mg autoinjector/syringe or as two 70 mg autoinjectors/syringes given consecutively at the same visit.
Injection sites are the abdomen, the thigh, or the outer upper arm. Sites are rotated between monthly doses to reduce injection-site reactions.
This is not a short course. Aimovig is taken for as long as it controls the migraine burden. Patients with meaningful response, typically defined as 50 percent reduction in monthly migraine days at the 3-month assessment, continue indefinitely. Patients without meaningful response after 3 months are reassessed and the treating neurologist considers switching to an anti-CGRP-ligand mAb, an oral gepant, or returning to conventional preventives.
Eligibility at a UAE neurologist's clinic
For UAE-resident patients, neurology services apply the FDA and EMA criteria with local insurance adaptation:
1. Confirmed diagnosis of migraine (episodic or chronic) by a neurologist or headache specialist applying ICHD-3 criteria. A headache diary covering 1 to 3 months is the standard supporting document. 2. At least 4 migraine days per month documented. Episodic migraine: 4 to 14 migraine days per month. Chronic migraine: 15 or more headache days per month with at least 8 migraine days. 3. Trial and failure (intolerance or contraindication) of at least 2 conventional oral preventives is the most common UAE insurance threshold. Topiramate, propranolol, amitriptyline, valproate, candesartan, and flunarizine are the usual previous trials. 4. Screening for medication overuse headache. Patients overusing acute medications (triptans, NSAIDs, ergots, opioids, or combination analgesics on 10 or more days per month for opioids/triptans, or 15 or more days per month for simple analgesics) need a parallel acute-withdrawal plan. 5. Screening for secondary causes of headache. Untreated hypertension, intracranial pathology, cervicogenic causes; usually already excluded by the time the patient reaches the CGRP conversation, but a quick re-check is standard. 6. Cardiovascular history review. Aimovig has post-marketing reports of hypertension; baseline blood pressure measurement is standard before initiation, with monitoring during treatment. 7. Constipation history review. Aimovig has a notable constipation signal that increases with the 140 mg dose. Patients with prior chronic constipation, IBS-C, or opioid-related constipation history warrant a frank conversation before initiation. 8. Pregnancy planning discussion for women of childbearing potential. Data is limited and the antibody has a long half-life; washout consideration matters if pregnancy is planned.
A UAE patient should arrive at the CGRP conversation with the most recent neurology documentation: a complete preventive-medication history with response durations and reasons for failure, a current headache diary if available, current and prior acute-medication use patterns (to screen for medication overuse headache), and the insurance pre-authorisation paperwork that the neurologist's office typically initiates.
The UAE prescribing and supply picture, plainly
Aimovig is registered with the Emirates Drug Establishment. Commercial supply runs through Novartis's MENA regional distributor network. The pathway is:
1. Prescribing neurologist with migraine/headache expertise: any board-certified UAE neurologist treating migraine. Headache-specialised neurology services are concentrated at the major UAE tertiary centres: Cleveland Clinic Abu Dhabi (neurology institute), American Hospital Dubai, Mediclinic City Hospital Dubai, Mediclinic Parkview, NMC Specialty and Aster Hospitals across Dubai and Sharjah, Burjeel Medical City, Saudi German Hospital Dubai, and the Dr Sulaiman Al Habib network. Public sector neurology at SKMC, Tawam, and Dubai Health Authority hospitals handles the same role for Emirati nationals. 2. Pharmacy dispensing: hospital pharmacy if prescribed in the inpatient or specialty outpatient setting; community pharmacy with cold-chain refrigeration capability for ongoing monthly dispensing. Aimovig must be stored at 2 to 8 degrees Celsius. It can be at room temperature (up to 25 C) for up to 7 days, after which the product should be discarded if not used (not returned to refrigeration). 3. Insurance pre-authorisation: Thiqa coverage for Emirati nationals has extended to CGRP preventive therapy on a case-by-case basis with documented prior-preventive failure and migraine-day threshold. Daman and the major commercial insurers (Oman Insurance, AXA Gulf, MetLife, Cigna, others) require similar documentation. The most common pre-authorisation friction point is documentation of 2 prior preventive failures; insurers sometimes specify which agents qualify as adequate trials. 4. Self-injection training: a single supervised session at the prescribing neurologist's clinic or a Novartis nurse educator visit is typical. The SureClick autoinjector is designed for straightforward patient use; most patients self-inject after 1 session. 5. Ongoing monitoring: neurology follow-up at 3 months for response assessment, then every 6 months for stable responders. Blood pressure check at each follow-up. Frank constipation review at each follow-up.
The 2026 pathway, step by step
Week 0 to 1: Reserve Meds builds the documentation pack with the treating neurologist's office. We collect the preventive-medication history, the headache diary if available, acute-medication usage patterns, current blood pressure readings, and insurance card details. The neurologist's office submits insurance pre-authorisation if applicable.
Week 1 to 4: Insurance pre-authorisation review. Most UAE commercial insurers turn this around within 2 to 4 weeks. Some require specific documentation of which preventives have been trialled and at what doses; we surface these requirements early.
Week 4 to 6: First dispensing at the neurologist's clinic or partner pharmacy. First dose of 70 mg administered (or self-administered under supervision) with self-injection training on the SureClick autoinjector.
Month 1 to 3: Patient self-injects monthly at home. Reserve Meds coordinates the cold-chain delivery for each monthly dose. The patient keeps a brief headache diary through the 3-month assessment window.
Month 3: Response assessment with the treating neurologist. Patients with 50% or greater reduction in monthly migraine days, or substantial improvement in attack intensity/duration, continue at 70 mg or step up to 140 mg if additional benefit is desired. Patients without meaningful response are reassessed and the neurologist considers switching to an anti-CGRP-ligand mAb (Ajovy, Emgality, Vyepti) or an oral gepant (Qulipta, Nurtec), or returning to conventional preventives.
Month 3 onwards: Maintenance dosing for as long as Aimovig controls the migraine burden. Neurology follow-up every 6 months for stable responders. Blood pressure check and constipation review at each follow-up.
Cost expectation in AED
US list price (WAC) for Aimovig is approximately USD 6,900 to 7,500 per year. MENA pharmacy pricing typically lands lower at the wholesale level; cash-pay retail pricing in regional specialty pharmacies commonly sits in the USD 400 to 700 per month range, giving an annual cash-pay band of roughly USD 4,800 to 8,400.
At 2026 indicative cross rates, the AED-equivalent annual cost band is approximately AED 18,000 to 31,000 at cash-pay retail. Insurance pre-authorisation reduces out-of-pocket exposure substantially for covered patients; cash-pay exposure depends on the dispensing pharmacy's regional pricing.
For Emirati nationals with Thiqa coverage, the financial pre-authorisation conversation needs to start before the first dispensing, not after. Daman and other commercial covers vary; the prescribing neurologist's office is the gating step.
What to monitor
The notable adverse-event signals for Aimovig are constipation and hypertension.
Constipation increases with dose; the 140 mg arm has a higher rate than the 70 mg arm. Most cases are mild to moderate and respond to dietary modification (fluid, fibre) and standard laxative use as needed. Serious constipation requiring hospitalisation has been reported in post-marketing experience and is a discontinuation indication. Patients with prior chronic constipation, IBS-C, or opioid-related constipation should discuss this frankly at initiation.
Hypertension. Post-marketing reports note new-onset or worsening hypertension in patients on Aimovig. Baseline blood pressure measurement is standard before initiation, with ongoing monitoring at each follow-up visit. New or worsening hypertension during treatment warrants neurology and primary-care coordination.
Injection-site reactions (redness, swelling, mild pain) are common and typically resolve as the patient learns the injection technique and rotates injection sites.
Hypersensitivity reactions, including rash, angioedema, and rare anaphylaxis, have been reported. Hypersensitivity is a discontinuation indication.
Live vaccines do not have a specific restriction for Aimovig; standard preventive-care vaccination is unaffected.
Long-term safety data through 5+ years of continuous use is reassuring; real-world data continues to accumulate.
Religious, ethical, and family-logistics framing
Aimovig is a recombinant humanised IgG2 monoclonal antibody produced in CHO cell lines. There is no donor element, no human or animal source material, no foreign genetic content in the patient. The classical analogy to vaccines and other injectable biologics holds in MENA Islamic medical ethics, where biologics are generally treated as permissive with the standard expectation that the patient and family decide in consultation with the treating physician.
The self-injection element is the practical pressure point for some UAE patients. Patients uncomfortable with home injection can request clinic-administered dispensing, though this adds friction and is rarely necessary given the SureClick autoinjector design. Most UAE patients are comfortable with self-injection after the initial training; the injection is subcutaneous, the volume is small, and the monthly cadence is forgiving.
The chronic-treatment nature of Aimovig means a years-long routine. UAE patient logistics should plan for cold-chain pharmacy access (most UAE community pharmacies handle this), travel-friendly storage (the 7-day room-temperature window allows for short trips), and neurology follow-up cadence.
Constipation deserves a separate cultural note. In some MENA family contexts, gastrointestinal symptoms are not discussed openly. The page acknowledges this directly: the constipation signal is real, the frank conversation at initiation matters, and a patient who develops constipation should report it to the neurologist rather than tolerate it silently.
When Aimovig is not the right call
For a UAE patient whose migraine burden does not meet preventive-therapy thresholds, where the disease is well controlled on conventional preventives, where untreated medication overuse headache is the dominant driver and acute-medication withdrawal is the appropriate first step, or where insurance pre-authorisation requires trials of specific oral preventives that have not yet been attempted, the operational pathway shifts:
- Ajovy (fremanezumab), Emgality (galcanezumab), Vyepti (eptinezumab): anti-CGRP-ligand mAbs; same prevention lane, different mechanism (binding the ligand rather than the receptor). Often interchangeable with Aimovig in the conversation about which CGRP agent to try first. - Qulipta (atogepant), Nurtec ODT (rimegepant): oral CGRP-receptor antagonists for prevention. Useful when injection is unacceptable to the patient or when oral preventive is preferred. - Conventional oral preventives: topiramate, propranolol, amitriptyline, valproate, candesartan, flunarizine. Lower cost, longer track record, often the required prior trials before a CGRP agent is approved. - Botox (onabotulinumtoxinA) with the PREEMPT protocol for chronic migraine; quarterly injections by a trained clinician. - Behavioural and non-pharmacological: sleep hygiene, hydration, trigger identification, cognitive behavioural therapy, biofeedback where indicated. Adjuncts in most cases.
Reserve Meds does not push a default. The page above describes the Aimovig pathway because Aimovig is the preventive the patient has asked about. If the conversation with the treating neurologist points toward an anti-ligand mAb, an oral gepant, Botox, or continued conventional preventives, the operational pathway shifts accordingly.
What Reserve Meds does on this case
We are a US-based concierge coordinator. We are not the prescriber and not the dispensing pharmacy. On a UAE Aimovig case we build the documentation pack with the treating neurologist's office, run the insurance pre-authorisation conversation alongside the clinical pre-authorisation conversation, coordinate the cold-chain supply logistics for ongoing monthly dispensing, organise self-injection training, and stay with the case through the first year of dosing with handoff to the local neurologist for ongoing surveillance. Clinical decisions remain with your treating neurologist.
Composite case examples; no individual patient is depicted. This content is for general information and does not constitute medical advice. Reserve Meds is a US-based concierge coordinator; we are not the prescriber and not the dispensing pharmacy. Clinical decisions remain with your treating neurologist.
Clinical and regulatory review: Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last medically reviewed: 2026-05-20.